

Francesco Tedesco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8359781/publications.pdf>

Version: 2024-02-01

106
papers

8,456
citations

47006

47
h-index

46799

89
g-index

110
all docs

110
docs citations

110
times ranked

9554
citing authors

#	ARTICLE	IF	CITATIONS
1	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. <i>Blood</i> , 2000, 95, 3900-3908.	1.4	523
2	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. <i>Nature Reviews Rheumatology</i> , 2011, 7, 330-339.	8.0	482
3	Thrombus formation induced by antibodies to β_2 -glycoprotein I is complement dependent and requires a priming factor. <i>Blood</i> , 2005, 106, 2340-2346.	1.4	324
4	The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity. <i>Journal of Experimental Medicine</i> , 1997, 185, 1619-1628.	8.5	289
5	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , 2014, 124, 1715-1726.	1.4	288
6	Inhibiting the C5a receptor axis. <i>Molecular Immunology</i> , 2011, 48, 1631-1642.	2.2	272
7	Complement in human diseases: Lessons from complement deficiencies. <i>Molecular Immunology</i> , 2009, 46, 2774-2783.	2.2	250
8	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. <i>Nature Communications</i> , 2016, 7, 10346.	12.8	224
9	Recruitment of circulating NK cells through decidual tissues: a possible mechanism controlling NK cell accumulation in the uterus during early pregnancy. <i>Blood</i> , 2008, 111, 3108-3115.	1.4	222
10	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. <i>Journal of Immunology</i> , 2011, 187, 172-180.	0.8	220
11	Complement activation in patients with COVID-19: A novel therapeutic target. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 215-217.	2.9	210
12	C1q: A fresh look upon an old molecule. <i>Molecular Immunology</i> , 2017, 89, 73-83.	2.2	188
13	Complement-Mediated Demyelination in Patients with IgM Monoclonal Gammopathy and Polyneuropathy. <i>New England Journal of Medicine</i> , 1990, 322, 649-652.	27.0	173
14	Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2319-2324.	7.1	171
15	Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population. <i>Frontiers in Immunology</i> , 2018, 9, 2664.	4.8	165
16	The complement system in the pathophysiology of pregnancy. <i>Molecular Immunology</i> , 2006, 43, 68-77.	2.2	156
17	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. <i>Cancer Research</i> , 2009, 69, 4001-4009.	0.9	153
18	<i>In vivo</i> Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab. <i>Cancer Research</i> , 2007, 67, 10556-10563.	0.9	141

#	ARTICLE	IF	CITATIONS
19	C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4209-4214.	7.1	140
20	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Frontiers in Immunology, 2020, 11, 584241.	4.8	137
21	The membrane attack complex of complement induces caspase activation and apoptosis. European Journal of Immunology, 2002, 32, 783.	2.9	136
22	An Alternative Role of C1q in Cell Migration and Tissue Remodeling: Contribution to Trophoblast Invasion and Placental Development. Journal of Immunology, 2010, 185, 4420-4429.	0.8	135
23	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity, 2021, 116, 102560.	6.5	127
24	Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood, 2000, 95, 3900-3908.	1.4	124
25	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood, 2007, 110, 536-543.	1.4	121
26	A non- α complement-fixing antibody to β 2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood, 2014, 123, 3478-3487.	1.4	120
27	In vivo distribution of β 2 glycoprotein I under various pathophysiologic conditions. Blood, 2011, 118, 4231-4238.	1.4	113
28	I. Adrenal Cortex and Steroid 21-Hydroxylase Autoantibodies in Adult Patients with Organ-Specific Autoimmune Diseases: Markers of Low Progression to Clinical Addison's Disease. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 932-938.	3.6	109
29	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. Nature Reviews Rheumatology, 2018, 14, 433-440.	8.0	95
30	Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. Journal of Allergy and Clinical Immunology, 2009, 124, 1303-1310.e4.	2.9	94
31	Serum-Resistant Strains of <i>Borrelia burgdorferi</i> Evade Complement-Mediated Killing by Expressing a CD59-Like Complement Inhibitory Molecule. Journal of Immunology, 2003, 170, 3214-3222.	0.8	92
32	Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. European Journal of Immunology, 2005, 35, 2175-2183.	2.9	92
33	Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity, 2006, 39, 417-428.	2.6	87
34	The Neutrophil-Activating Protein of <i>Helicobacter pylori</i> Crosses Endothelia to Promote Neutrophil Adhesion In Vivo. Journal of Immunology, 2007, 178, 1312-1320.	0.8	87
35	Platelet-Activating Factor and Kinin-Dependent Vascular Leakage as a Novel Functional Activity of the Soluble Terminal Complement Complex. Journal of Immunology, 2004, 173, 6921-6927.	0.8	85
36	Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Molecular Immunology, 2008, 45, 2629-2640.	2.2	82

#	ARTICLE	IF	CITATIONS
37	An immunohistochemical study of leucocytes in human endometrium, first and third trimester basal decidua. <i>Journal of Reproductive Immunology</i> , 1993, 23, 41-49.	1.9	81
38	Bilirubin inhibits the TNF α -related induction of three endothelial adhesion molecules. <i>Biochemical and Biophysical Research Communications</i> , 2009, 386, 338-344.	2.1	76
39	VE-cadherin is a critical molecule for trophoblast-endothelial cell interaction in decidual spiral arteries. <i>Experimental Cell Research</i> , 2004, 303, 101-113.	2.6	75
40	Chemerin Regulates NK Cell Accumulation and Endothelial Cell Morphogenesis in the Decidua during Early Pregnancy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3603-3612.	3.6	75
41	Cytolytically inactive terminal complement complex causes transendothelial migration of polymorphonuclear leukocytes in vitro and in vivo. <i>Blood</i> , 2002, 99, 185-192.	1.4	72
42	Complement as effector system in cancer immunotherapy. <i>Immunology Letters</i> , 2007, 111, 6-13.	2.5	72
43	Complement activation in animal and human pregnancies as a model for immunological recognition. <i>Molecular Immunology</i> , 2011, 48, 1621-1630.	2.2	71
44	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , 2016, 127, 365-367.	1.4	67
45	EMILIN1 represents a major stromal element determining human trophoblast invasion of the uterine wall. <i>Journal of Cell Science</i> , 2006, 119, 4574-4584.	2.0	62
46	Cross-talk between the complement and the kinin system in vascular permeability. <i>Immunology Letters</i> , 2011, 140, 7-13.	2.5	56
47	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018, 9, 1388.	4.8	51
48	Complement production by trophoblast cells at the feto-maternal interface. <i>Journal of Reproductive Immunology</i> , 2009, 82, 119-125.	1.9	50
49	Experimental Induction of Myelin Changes by Anti-MAG Antibodies and Terminal Complement Complex. <i>Journal of Neuropathology and Experimental Neurology</i> , 1995, 54, 96-104.	1.7	45
50	C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. <i>Blood</i> , 2009, 113, 3640-3648.	1.4	44
51	Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth. <i>Frontiers in Immunology</i> , 2017, 8, 1559.	4.8	44
52	Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. <i>Biomedicines</i> , 2021, 9, 1003.	3.2	44
53	Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain. <i>European Journal of Immunology</i> , 2003, 33, 1260-1270.	2.9	42
54	The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. <i>European Journal of Immunology</i> , 2002, 32, 2773-2782.	2.9	40

#	ARTICLE	IF	CITATIONS
55	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019, 104, 819-826.	3.5	40
56	Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. <i>Arthritis and Rheumatism</i> , 2012, 64, 2559-2567.	6.7	39
57	Complement Activated by Chimeric Anti-Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian Carcinoma. <i>Cancer Research</i> , 2006, 66, 3876-3883.	0.9	36
58	Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2019, 103, 102288.	6.5	33
59	Inherited Deficiencies of the Terminal Complement Components. <i>International Reviews of Immunology</i> , 1993, 10, 51-64.	3.3	32
60	Biosynthesis of C3 by human mesangial cells. Modulation by proinflammatory cytokines. <i>Kidney International</i> , 1995, 47, 829-836.	5.2	32
61	Inherited complement deficiencies and bacterial infections. <i>Vaccine</i> , 2008, 26, 13-18.	3.8	32
62	Orchestration of Inflammation and Adaptive Immunity in <i>Borrelia burgdorferi</i> -Induced Arthritis by Neutrophil-Activating Protein A. <i>Arthritis and Rheumatism</i> , 2013, 65, 1232-1242.	6.7	32
63	Complement as a Biological Tool to Control Tumor Growth. <i>Frontiers in Immunology</i> , 2018, 9, 2203.	4.8	31
64	Critical Role and Therapeutic Control of the Lectin Pathway of Complement Activation in an Abortion-Prone Mouse Mating. <i>Journal of Immunology</i> , 2015, 195, 5602-5607.	0.8	30
65	Complement component C1q potential diagnostic but not predictive marker of preeclampsia. <i>American Journal of Reproductive Immunology</i> , 2016, 76, 475-481.	1.2	30
66	The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy. <i>Frontiers in Immunology</i> , 2020, 11, 2084.	4.8	30
67	Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. <i>Arthritis and Rheumatism</i> , 2007, 56, 1187-1197.	6.7	29
68	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. <i>Rheumatology</i> , 2008, 48, 293-298.	1.9	29
69	In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging. <i>Molecular Imaging</i> , 2008, 7, 7290.2008.00028.	1.4	29
70	Alternative functions of the complement protein C1q at embryo implantation site. <i>Journal of Reproductive Immunology</i> , 2017, 119, 74-80.	1.9	29
71	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 773.	4.8	28
72	Early regulators in abortion and implications for a preeclampsia model. <i>Journal of Reproductive Immunology</i> , 2009, 82, 132-141.	1.9	26

#	ARTICLE	IF	CITATIONS
73	Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. <i>Autoimmunity Reviews</i> , 2019, 18, 561-563.	5.8	25
74	Endothelial cells are a target of both complement and kinin system. <i>International Immunopharmacology</i> , 2008, 8, 143-147.	3.8	24
75	Posttransplant Ischemia-Reperfusion Injury In Transplanted Heart Is Prevented By A Minibody to the Fifth Component of Complement. <i>Transplantation</i> , 2008, 86, 1445-1451.	1.0	24
76	Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5. <i>PLoS ONE</i> , 2013, 8, e58696.	2.5	24
77	Placental Trophoblast and Endothelial Cells as Target of Maternal Immune Response. <i>Autoimmunity</i> , 2003, 36, 11-18.	2.6	23
78	Effect of cytokines on the secretion of the fifth and eighth complement components by HepG2 cells. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 45-48.	1.0	21
79	An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies. <i>Current Pharmaceutical Design</i> , 2008, 14, 2023-2039.	1.9	20
80	Targeted Delivery of Neutralizing Anti-C5 Antibody to Renal Endothelium Prevents Complement-Dependent Tissue Damage. <i>Frontiers in Immunology</i> , 2017, 8, 1093.	4.8	20
81	The J-elongated conformation of $\hat{\text{I}}^2$ -glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome. <i>Journal of Biological Chemistry</i> , 2020, 295, 10794-10806.	3.4	20
82	Hepatocyte Nuclear Factor $\hat{\text{I}}^{\pm}$ Controls the Expression of Terminal Complement Genes. <i>Journal of Experimental Medicine</i> , 2001, 194, 1683-1690.	8.5	19
83	MBL Interferes with Endovascular Trophoblast Invasion in Pre-Eclampsia. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	19
84	Humoral immunotherapy of multiple myeloma: perspectives and perplexities. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 863-873.	3.1	16
85	Complement Activation and Thrombin Generation by MBL Bound to $\hat{\text{I}}^2$ -Glycoprotein I. <i>Journal of Immunology</i> , 2020, 205, 1385-1392.	0.8	16
86	Decidual-trophoblast interactions: decidual lymphoid cell populations in basal and parietal decidua. <i>Journal of Reproductive Immunology</i> , 1995, 28, 165-171.	1.9	14
87	In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. <i>Molecular Imaging</i> , 2008, 7, 272-82.	1.4	14
88	An allosteric redox switch in domain V of $\hat{\text{I}}^2$ -glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. <i>Journal of Biological Chemistry</i> , 2021, 297, 100890.	3.4	10
89	$\hat{\text{I}}^2$ Chain deficiency in three patients with dysfunctional C8 molecules. <i>Molecular Immunology</i> , 1983, 20, 47-51.	2.2	8
90	Terminal Complement Complex: Regulation of Formation and Pathophysiological Functions. , 2004, , 97-127.		8

#	ARTICLE	IF	CITATIONS
91	Î²2 glycoprotein I participates in phagocytosis of apoptotic neurons and in vascular injury in experimental brain stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 0271678X2098455.	4.3	8
92	An insight into normal and pathological pregnancies using large-scale microarrays: lessons from microarrays. <i>Journal of Reproductive Immunology</i> , 2011, 89, 163-172.	1.9	7
93	Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma. <i>Current Clinical Pharmacology</i> , 2010, 5, 246-250.	0.6	6
94	Distinct Roles of Classical and Lectin Pathways of Complement in Preeclamptic Placentae. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	6
95	An electrophysiological study of the effects of myasthenia gravis sera and complement on rat isolated muscle fibres. <i>Journal of Neuroimmunology</i> , 1993, 45, 155-162.	2.3	5
96	European Union funded project on the development of a whole complement deficiency screening ELISA—A story of success and an exceptional manager: Mohamed R. Daha. <i>Molecular Immunology</i> , 2015, 68, 63-66.	2.2	3
97	Role of the B1 Bradykinin Receptor and gC1qR/p33 in Angioedema. <i>Immunology and Allergy Clinics of North America</i> , 2013, 33, 535-544.	1.9	2
98	Memories of Bob Sim—Genius Complementologist and Cheerful Travel Companion. <i>Viruses</i> , 2021, 13, 1068.	3.3	2
99	Complement in autoimmunity and tissue injury. <i>Autoimmunity</i> , 2006, 39, 355-356.	2.6	1
100	The membrane attack complex of complement induces caspase activation and apoptosis. , 2002, 32, 783.		1
101	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?. , 2012, , 79-101.		1
102	The complement system at the feto-maternal interface: friend or foe?. <i>American Journal of Reproductive Immunology</i> , 2002, 48, 142-143.	1.2	0
103	ABSTRACTS: 12—The complement component C1q: A novel angiogenic factor?. <i>American Journal of Reproductive Immunology</i> , 2008, 60, 89-89.	1.2	0
104	C8. , 2000, , 123-130.		0
105	CCL3 and CCL4, the Major Chemokines Produced by CD38+ Chronic Lymphocytic Leukemia Cells, Facilitate Microenvironmental Interactions of Neoplastic Cells Via the CD49d/VCAM Pair.. <i>Blood</i> , 2008, 112, 1055-1055.	1.4	0
106	Monocytes/Macrophages Are the Major Targets of the CCL3 Chemokine Produced by CD38+CD49d+ Chronic Lymphocytic Leukemia Cells.. <i>Blood</i> , 2009, 114, 2350-2350.	1.4	0